Capricor Therapeutics Shares Outstanding History (CAPR)
Capricor Therapeutics reported 57.4M shares outstanding at the end of fiscal 2025.
View full Capricor Therapeutics company overviewCapricor Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 57.4M | 11.8M | +25.86% |
| 2024 | 2024-12-31 | 45.6M | 14.4M | +46.34% |
| 2023 | 2023-12-31 | 31.1M | 5.9M | +23.40% |
| 2022 | 2022-12-31 | 25.2M | 1.1M | +4.37% |
| 2021 | 2021-12-31 | 24.2M | 3.6M | +17.53% |
| 2020 | 2020-12-31 | 20.6M | 15.3M | +293.64% |
| 2019 | 2019-12-31 | 5.2M | 4.9M | +1565.44% |
| 2018 | 2018-12-31 | 313,874.8 | 51,169.89 | +19.48% |
| 2017 | 2017-12-31 | 262,704.91 | 48,714.72 | +22.76% |
| 2016 | 2016-12-31 | 213,990.19 | 51,440.34 | +31.65% |
| 2015 | 2015-12-31 | 162,549.85 | 45,479.34 | +38.85% |
| 2014 | 2014-12-31 | 117,070.51 | 193.04 | +0.17% |
| 2013 | 2013-12-31 | 116,877.47 | 13,364.53 | +12.91% |
| 2012 | 2012-12-31 | 103,512.94 | −293,609.37 | −73.93% |
| 2011 | 2011-12-31 | 397,122.31 | 50,824.37 | +14.68% |
| 2010 | 2010-12-31 | 346,297.94 | — | — |
Capricor Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 58.1M | 12.4M | +27.12% |
| Q1 2026 | 2026-03-31 | 57.7M | 12.0M | +26.24% |
| Q4 2025 | 2025-12-31 | 57.4M | 11.8M | +25.86% |
| Q3 2025 | 2025-09-30 | 45.7M | 5.4M | +13.35% |
| Q2 2025 | 2025-06-30 | 45.7M | 13.7M | +42.92% |
| Q1 2025 | 2025-03-31 | 45.7M | 14.1M | +44.55% |
| Q4 2024 | 2024-12-31 | 45.6M | 14.4M | +46.34% |
| Q3 2024 | 2024-09-30 | 40.3M | 14.5M | +55.99% |
| Q2 2024 | 2024-06-30 | 32.0M | 6.2M | +24.14% |
| Q1 2024 | 2024-03-31 | 31.6M | 6.3M | +25.12% |
| Q4 2023 | 2023-12-31 | 31.1M | 5.9M | +23.40% |
| Q3 2023 | 2023-09-30 | 25.9M | 1.2M | +4.67% |
| Q2 2023 | 2023-06-30 | 25.8M | 1.4M | +5.87% |
| Q1 2023 | 2023-03-31 | 25.3M | 930,998 | +3.83% |
| Q4 2022 | 2022-12-31 | 25.2M | 1.1M | +4.37% |
| Q3 2022 | 2022-09-30 | 24.7M | 553,529 | +2.29% |
| Q2 2022 | 2022-06-30 | 24.3M | 1.3M | +5.81% |
| Q1 2022 | 2022-03-31 | 24.3M | 1.5M | +6.69% |
| Q4 2021 | 2021-12-31 | 24.2M | 3.6M | +17.53% |
| Q3 2021 | 2021-09-30 | 24.1M | 3.9M | +19.48% |
| Q2 2021 | 2021-06-30 | 23.0M | 3.3M | +16.76% |
| Q1 2021 | 2021-03-31 | 22.8M | 13.6M | +148.11% |
| Q4 2020 | 2020-12-31 | 20.6M | 15.3M | +293.64% |
| Q3 2020 | 2020-09-30 | 20.2M | 16.0M | +384.13% |
| Q2 2020 | 2020-06-30 | 19.7M | 16.2M | +468.07% |
| Q1 2020 | 2020-03-31 | 9.2M | 8.9M | +2629.69% |
| Q4 2019 | 2019-12-31 | 5.2M | 4.9M | +1565.43% |
| Q3 2019 | 2019-09-30 | 4.2M | 3.9M | +1257.73% |
| Q2 2019 | 2019-06-30 | 3.5M | 3.2M | +1056.04% |
| Q1 2019 | 2019-03-31 | 336,613.46 | 56,904.67 | +20.34% |
| Q4 2018 | 2018-12-31 | 313,877.29 | 51,172.38 | +19.48% |
| Q3 2018 | 2018-09-30 | 307,488.72 | 56,484.84 | +22.50% |
| Q2 2018 | 2018-06-30 | 299,943.16 | 73,990.06 | +32.75% |
| Q1 2018 | 2018-03-31 | 279,708.79 | 65,718.6 | +30.71% |
| Q4 2017 | 2017-12-31 | 262,704.91 | 48,714.72 | +22.76% |
| Q3 2017 | 2017-09-30 | 251,003.88 | 37,013.69 | +17.30% |
| Q2 2017 | 2017-06-30 | 225,953.1 | 46,429.87 | +25.86% |
| Q1 2017 | 2017-03-31 | 213,990.19 | 34,466.96 | +19.20% |
| Q4 2016 | 2016-12-31 | 213,990.19 | 51,440.34 | +31.65% |
| Q3 2016 | 2016-09-30 | 213,990.19 | 51,440.34 | +31.65% |
| Q2 2016 | 2016-06-30 | 179,523.23 | 17,290.42 | +10.66% |
| Q1 2016 | 2016-03-31 | 179,523.23 | 17,303.38 | +10.67% |
| Q4 2015 | 2015-12-31 | 162,549.85 | 45,479.34 | +38.85% |
| Q3 2015 | 2015-09-30 | 162,549.85 | 45,512.11 | +38.89% |
| Q2 2015 | 2015-06-30 | 162,232.81 | 45,282.73 | +38.72% |
| Q1 2015 | 2015-03-31 | 162,219.85 | 45,311.26 | +38.76% |
| Q4 2014 | 2014-12-31 | 117,070.51 | 193.04 | +0.17% |
| Q3 2014 | 2014-09-30 | 117,037.74 | −318,167.89 | −73.11% |
| Q2 2014 | 2014-06-30 | 116,950.08 | −313,672.23 | −72.84% |
| Q1 2014 | 2014-03-31 | 116,908.59 | −313,713.72 | −72.85% |
| Q4 2013 | 2013-12-31 | 116,877.47 | −313,744.84 | −72.86% |
| Q3 2013 | 2013-09-30 | 435,205.63 | 4,583.32 | +1.06% |
| Q2 2013 | 2013-06-30 | 430,622.31 | 33,500 | +8.44% |
| Q1 2013 | 2013-03-31 | 430,622.31 | 33,500 | +8.44% |
| Q4 2012 | 2012-12-31 | 430,622.31 | 33,544.67 | +8.45% |
| Q2 2012 | 2012-06-30 | 430,622.31 | 33,544.67 | +8.45% |
| Q1 2012 | 2012-03-31 | 397,122.31 | 50,824.37 | +14.68% |
| Q4 2011 | 2011-12-31 | 397,122.31 | — | — |
| Q3 2011 | 2011-09-30 | 397,077.64 | — | — |
| Q2 2011 | 2011-06-30 | 397,077.64 | — | — |
| Q4 2010 | 2010-12-31 | 346,297.94 | — | — |
Capricor Therapeutics shares outstanding trends
Over the last five reported fiscal years, Capricor Therapeutics's shares outstanding moved from 20.6M to 57.4M, a change of 36.8M. The latest reported quarter, Q2 2026, shows 58.1M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Capricor Therapeutics filings at SEC.gov ↗